BBC NEWS
 'Dramatic results' in eye gene op
 US scientists have
 claimed success using gene therapy to
 try to reverse a severe inherited sight disorder.
 They injected material
 containing a corrective gene into
 the eyes of three patients with Leber congenital amaurosis (LCA).
 The journal Proceedings
 of the National Academy of Sciences
 reports all three showed signs of "significant" improvement in their vision.
 UK researchers carried
 out a similar procedure on three
 patients last year.
 They believe the method
 could be ready for use within two
 years to treat people suffering from some
 inherited diseases of the retina, which
 affect 20,000 people in Britain.
 Within three years,
 they believe it could be ready for testing
 on people who suffer age related macular
 degeneration, a condition that affects 500,000
 Britons.
 The paper adds to the
 body of evidence supporting the value
 of gene therapy for people with inherited disease
 Dr James Bainbridge
 Institute of Ophthalmology
 Gene therapy works on a
 simple principle - to replace a
 malfunctioning gene, and restore function to a
 part of the body affected by a genetic
 disorder.
 In practice, however,
 it has proved very difficult to find
 ways to introduce the new gene copies in the
 correct tissues, and experiments in
 animals have had mixed results.
 In the eye, however,
 gene therapy has shown more promise.
 LCA affects
 approximately one in 80,000 people, causing
 progressively worsening vision, often starting in the first few years of life.
 It is responsible for
 one in 10 severe sight disorders in
 children.
 A fault in the RPE65
 gene is to blame, and the gene therapy
 injects working copies of the gene into the back of the eye.
 Just 30 days after the
 treatment was delivered into one
 eye of each of the three young adults involved in
 the US study, the improvements
 could be measured.
 The researchers, from
 Pennsylvania University, the University
 of Florida and Cornell University, suggested that
 the function of "cones" in the
 retina, which are used in daytime and colour
 vision, could be boosted up to 50-fold
 - a "dramatic" improvement in function.
 However, vision in the
 treated eyes was not perfect - with
 the patients showing an abnormally slow adaptation to low light levels.
 UK first
 In the UK, scientists
 and doctors at the Institute of Ophthalmology
 and Moorfields Eye Hospital in London have been
 working for some years on a similar
 approach.
 In 2007, they were the
 first to perform a gene therapy operation
 on three people with LCA, and earlier this year
 reported significant improvement
 in one of these.
 Dr James Bainbridge,
 one of the Institute of Ophthalmology
 researchers involved, said the US findings were a
 step forward, helping to fine tune
 the technique and maximising the chances of success.
 He said: "This paper is
 important because it provides further
 evidence that gene replacement therapy can
 improve vision in people with this form
 of LCA.
 "It also confirms the
 prediction that the extent of improvement
 depends on the number of surviving target cells
 at the time of intervention, and
 shows that both rod and cone photoreceptor cells can benefit.
 "The paper adds to the
 body of evidence supporting the value
 of gene therapy for people with inherited disease."
 Professor Robin Ali,
 who also worked on the UK study, said
 the latest paper gave scientists a much better
 idea of what dose of gene therapy
 would give the best results.
 He said: "We can now
 begin to find out how much useful vision
 is restored by improving retinal sensitivity and
 whether the results are better in
 young children when we treat the whole retina using a high dose."
 Story from BBC NEWS:



      Download prohibited? No problem. CHAT from any browser, without download. 
Go to http://in.webmessenger.yahoo.com/

Thanks to all for making the convention successful; thanks also to Blind 
Person's Association for the whole hearted support.
To unsubscribe send a message to [EMAIL PROTECTED] with the subject unsubscribe.

To change your subscription to digest mode or make any other changes, please 
visit the list home page at
  http://accessindia.org.in/mailman/listinfo/accessindia_accessindia.org.in

Reply via email to